- Home
- RCKT vs IPSC Comparison
RCKT vs IPSC Comparison
Compare RCKT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | IPSC |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.6M | 413.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RCKT | IPSC |
|---|---|---|
| Price | $3.62 | $2.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $29.73 | $4.25 |
| AVG Volume (30 Days) | ★ 2.0M | 843.0K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $64.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $2.19 | $0.44 |
| 52 Week High | $6.89 | $2.97 |
Technical Indicators
Market Signals| Indicator | RCKT | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 49.62 |
| Support Level | $3.32 | $2.15 |
| Resistance Level | $4.08 | $2.67 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 48.46 | 46.67 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.